Form 4: Immix Biopharma Director Receives Equity Grant

Director Yekaterina Chudnovsky was granted 6,250 restricted stock units and 12,500 stock options by Immix Biopharma, Inc.

Summary

• Director Yekaterina Chudnovsky received a grant of 6,250 restricted stock units (RSUs) on May 22, 2026.
• The director was also granted 12,500 stock options with an exercise price of $8.78 per share.
• The RSUs vest on the earlier of the one-year anniversary of the grant or the 2027 annual meeting.
• The stock options vest in equal monthly installments over 12 months, subject to continued service.
• The reporting person maintains indirect beneficial ownership of 3,241,076 shares through GKCC, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the company's immediate financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Retention of key leadership through structured vesting schedules.

Negatives

• Dilutive impact of new equity grants on existing shareholders.

Risks

• Continued service requirement for vesting creates dependency on director retention.
• Market price volatility could impact the value of the granted options.

Future Outlook

The equity grants are subject to continued service requirements, with vesting tied to the one-year anniversary of the grant or the 2027 annual meeting of stockholders.

Management Comments

• The reporting person is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure alignment between directors and shareholders during long-term drug development cycles.

Comparison to Industry Standards

• The use of 12-month vesting schedules for director equity is consistent with standard practices for small-cap biotech firms.
• The inclusion of a 'vesting on annual meeting' clause is a common mechanism to align director terms with the annual election cycle.

Corporate Governance

Related Party Transactions

• The reporting person maintains indirect beneficial ownership of 3,241,076 shares through GKCC, LLC.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of RSUs on the earlier of May 22, 2027, or the 2027 Annual Meeting.
• Monthly vesting of stock options over the next 12 months.

Key Dates

Keywords

Immix Biopharma, IMMX, Form 4, Equity Compensation, Director Compensation, Insider Transaction